7 recruiting, 4 active not recruiting, 3 completed, 3 unknown. 11 Phase 1, 7 Phase 2, 5 Phase 3.
Follow Beijing Mabworks Biotech Co., Ltd.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 3 Clinical Study of MIL62 in Systemic Lupus Erythematosus MIL62, Placebo - Systemic Lupus Erythematosus | Phase 3 | Recruiting | Beijing Mabworks Biotech Co., Ltd. | 316 | 2026-04-10 | 2026-05-05 |
| A Study of MIL116 in Healthy Participants and Patients With IgA Nephropathy. MIL116, Matching Placebo - Immunoglobulin A Nephropathy | Phase 1 / Phase 2 | Recruiting | Beijing Mabworks Biotech Co., Ltd. | 130 | 2026-02-05 | 2026-04-13 |
| A Study of MBS314 in Participants With Relapsed/Refractory Multiple Myeloma. MBS314 Injection - Relapsed or Refractory Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | Beijing Mabworks Biotech Co., Ltd. | 154 | 2024-02-22 | 2024-03-15 |
| A Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy Study of MBS303 in B-Cell NHL MBS303 - Non-Hodgkin's Lymphoma | Phase 1 / Phase 2 | Recruiting | Beijing Mabworks Biotech Co., Ltd. | 132 | 2023-06-28 | 2024-11-20 |
| A Phase Ⅲ Clinical Study of MIL62 in Primary Membranous Nephropathy MIL62, Cyclosporine - Primary Membranous Nephropathy | Phase 3 | Active not recruiting | Beijing Mabworks Biotech Co., Ltd. | 150 | 2023-06-02 | 2025-08-20 |
| A Phase 2 Clinical Study of MIL62 in Systemic Lupus Erythematosus MIL62, placebo - Systemic Lupus Erythematosus | Phase 2 | Active not recruiting | Beijing Mabworks Biotech Co., Ltd. | 120 | 2023-05-26 | 2025-12-19 |
| A Study of MIL62 in Patients With Neuromyelitis Optica Spectrum Disorder (NMOSD) MIL62, Placebo - Neuromyelitis Optica Spectrum Disorder | Phase 3 | Active not recruiting | Beijing Mabworks Biotech Co., Ltd. | 102 | 2022-08-18 | 2025-09-25 |
| A Phase Ib/ Ⅱ Clinical Study of MIL62 in Primary Membranous Nephropathy MIL62, Cyclosporine - Primary Membranous Nephropathy | Phase 1 / Phase 2 | Completed | Beijing Mabworks Biotech Co., Ltd. | 94 | 2022-02-24 | 2025-11-17 |
| Treatment of Advanced and Metastatic Solid Tumors With MIL97 Recombinant Humanized Monoclonal Antibody MIL97 for Injection - Advanced or Metastatic Solid Tumor | Phase 1 | Recruiting | Beijing Mabworks Biotech Co., Ltd. | 62 | 2022-01-18 | 2024-03-13 |
| Evaluation of the Tolerance, Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of MIL62 Injection for Treating Lupus Nephritis Recombinant Humanized Monoclonal Antibody MIL62 Injection, placebo - Lupus Nephritis | Phase 1 / Phase 2 | Active not recruiting | Beijing Mabworks Biotech Co., Ltd. | 41 | 2021-11-26 | 2025-07-02 |
| MIL62 Combined With Lenalidomide Versus Lenalidomide for Patients With Rituximab Refractory Follicular Lymphoma Recombinant Humanized Monoclonal Antibody MIL62, lenalinomide, lenalinomide - Follicular Lymphoma and Marginal Zone Lymphoma | Phase 3 | Recruiting | Beijing Mabworks Biotech Co., Ltd. | 168 | 2021-06-02 | 2024-11-20 |
| A Clinical Study of MIL93 in Solid Tumors. Recombinant Humanized Monoclonal Antibody MIL93 - Advanced Malignancies | Phase 1 | Unknown | Beijing Mabworks Biotech Co., Ltd. | 228 | 2021-04-21 | 2024-03-13 |
| A Clinical Study of MIL95 in Advanced Malignancies. Recombinant Humanized Monoclonal Antibody MIL95 - Advanced Malignancies | Phase 1 | Unknown | Beijing Mabworks Biotech Co., Ltd. | 58 | 2021-01-04 | 2024-11-20 |
| MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL and MZL) Recombinant Humanized Monoclonal Antibody MIL62 Injection, Lenalidomide - Follicular Lymphoma and Marginal Zone Lymphoma | Phase 1 / Phase 2 | Recruiting | Beijing Mabworks Biotech Co., Ltd. | 53 | 2019-11-28 | 2024-11-20 |
| Phase I Clinical Study of MBS301 in Treatment of HER2 Positive Recurrent or Metastatic Malignant Solid Tumor Recombinant Humanized Bispecific Monoclonal Antibody MBS301 - HER2-positive Recurrent or Metastatic Malignant Solid Tumor | Phase 1 | Unknown | Beijing Mabworks Biotech Co., Ltd. | 34 | 2019-04-11 | 2024-11-20 |
| mil60 Versus Bevacizumab in Patients With Treatment-naïve Non-squamous Non-small Cell Lung Cancer mil60, Bevacizumab - Non-small Cell Lung Cancer | Phase 3 | Completed | Beijing Mabworks Biotech Co., Ltd. | 517 | 2017-08-15 | 2023-01-31 |
| A Study of MIL62 in Treatment of CD20 Positive B-cell Lymphomas Recombinant Humanized Monoclonal Antibody MIL62 Injection - CD20-positive B Cell Non-Hodgkin Lymphoma | Phase 1 | Completed | Beijing Mabworks Biotech Co., Ltd. | 27 | 2017-02-10 | 2025-05-18 |
Lupus Erythematosus, Systemic (2) · Lymphoma, B-Cell, Marginal Zone (2) · Lymphoma, Follicular (2) · Neoplasm Metastasis (2) · Carcinoma, Non-Small-Cell Lung (1) · Glomerulonephritis, IGA (1) · Lupus Nephritis (1) · Lymphoma, Non-Hodgkin (1) · Multiple Myeloma (1) · Neuromyelitis Optica (1) · Recurrence (1)
Cyclosporine (2) · Bevacizumab (1) · Injections (1) · Lenalidomide (1)
China (17)
Jie Wang, MD (1) · Lugui Qiu, Doctor (1) · Yuankai Shi (1) · Yuankai Shi, MD (1)